News & Insights
AI could take ‘years’ off the drug development process, says Bausch + Lomb CEO Brent Saunders
Brent joined “Squawk on the Street” to discuss the impacts of artificial intelligence on health care, Bausch + Lomb’s latest earnings report, and more.
Bausch + Lomb CEO: Standing still is the new falling behind
In a piece for Fortune, Brent covers the AI upskilling imperative and why he we made AI training mandatory for 8,000+ employees at Bausch + Lomb.
Brent Saunders: Eyeing New Horizons
Pharmaceutical Executive highlights Bausch + Lomb’s transformation under Brent, with a focus on the company’s rebuilt pipeline.
Q&A: Brent Saunders on pushing Bausch out of neutral, scrutinizing new hires and why TrumpRx matters
Brent speaks with Senior Biopharma Correspondent Andrew Dunn for an Endpoints News feature.
Bausch + Lomb CEO Brent Saunders on growth outlook: Biggest contributor will be in surgical
Brent joins CNBC’s “Squawk Box” live in studio.
Bausch + Lomb CEO Brent Saunders on Comeback, R&D Innovation, and Eye Care’s Evolution
Brent joins the New York Stock Exchange’s “Inside the ICE House” podcast for a wide-ranging interview in advance of Bausch + Lomb Investor Day.
AI could take ‘years’ off the drug development process, says Bausch + Lomb CEO Brent Saunders
Brent joined “Squawk on the Street” to discuss the impacts of artificial intelligence on health care, Bausch + Lomb’s latest earnings report, and more.
Bausch + Lomb CEO: Standing still is the new falling behind
In a piece for Fortune, Brent covers the AI upskilling imperative and why he we made AI training mandatory for 8,000+ employees at Bausch + Lomb.
Brent Saunders: Eyeing New Horizons
Pharmaceutical Executive highlights Bausch + Lomb’s transformation under Brent, with a focus on the company’s rebuilt pipeline.
Q&A: Brent Saunders on pushing Bausch out of neutral, scrutinizing new hires and why TrumpRx matters
Brent speaks with Senior Biopharma Correspondent Andrew Dunn for an Endpoints News feature.